No Data
Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference
Protara's IV Choline Chloride Receives FDA Fast Track Designation for Patients on Parenteral Support
Express News | Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support
Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), MoonLake Immunotherapeutics (MLTX) and Protara Therapeutics (TARA)
Opaleye Management Inc. Reduces Stake in Protara Therapeutics Inc.
TD Cowen Maintains Protara Therapeutics(TARA.US) With Buy Rating
TD Cowen analyst Stacy Ku maintains $Protara Therapeutics(TARA.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 53.1% and a total average return of -3.7% over the
No Data
No Data